Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer
Status:
Completed
Trial end date:
2005-05-01
Target enrollment:
Participant gender:
Summary
- Assess the safety and tolerance of a weekly MEDI522 regimen in patients with
irinotecan-refractory advanced CRC or other solid tumors refractory to standard therapy.